Effect of olmesartan medoxomil on renal oxidative stress in mice with chronic heart failure
LU Xiao-mei, MA Ling, YU Yan-qiu
Author information+
Department of Pathophysiology, College of Basic Medical Sciences, China Medical University, Shenyang 110001, ChinaCorresponding author：YU Yan-qiu，Email：yqyu@mail.cmu.edu.cn
{{custom_zuoZheDiZhi}}
{{custom_authorNodes}}
{{custom_bio.content}}
{{custom_bio.content}}
Collapse
History+
Received
Revised
Published
1900-01-01
1900-01-01
2011-03-15
Issue Date
2011-03-15
Abstract
Objective To investigate the effect of olmesartan medoxomil on renal oxidative stress in mice with chronic heart failure. Methods C57 mice were divided into sham operation group (SHAM group), chronic heart failure group (CHF group) and olmesartan medoxomil treatment group (OLM group). Experimental CHF model was established by coronary artery ligation, in which OLM group fed with a daily dose of 10 mg/kg. The heart rate, blood pressure, cardiac function, Scr, BUN, and plasma and kidney angiotensin (Ang) Ⅱ were measured. Real-time PCR was used to examine renal gp91phox, p22phox and NOX4 expression. AZAN and DHE staining was used to detect renal pathological change after 12 weeks． Results Compared with SHAM group, left ventricular-end diastolic dimension (LVDd) and left ventricular end-systolic dimension(LVDs) were significantly increased (P<0.05), while fractional shortening (FS) and ejection fraction (EF) were significantly decreased in CHF and OLM groups (P<0.05). Compared with SHAM group, systolic blood pressure, Scr, BUN, and AZAN and DHE staining positive area were significantly increased in CHF group (P<0.05), while above indexes were significantly lower in OLM group as compared to CHF group (P<0.05). Compared with SHAM group, plasma and kidney AngⅡ levels, gp91phox, p22phox and NOX4 expression were increased in CHF group (P<0.05), while above indexes were significantly lower in OLM group as compared to CHF group (P<0.05). Conclusions Chronic heart failure can activate intrarenal NADPH oxidase resulting in renal injury. Olmesartan medoxomil can protect kidney by inhibiting the effect of Ang Ⅱ-induced oxidative stress.
LU Xiao-mei;MA Ling;YU Yan-qiu.
Effect of olmesartan medoxomil on renal oxidative stress in mice with chronic heart failure[J]. Chinese Journal of Nephrology, 2011, 27(3): 190-193.
PDF(425 KB)
